Exhibit 99.1

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma -

- Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 in ovarian cancer in 2022 -

- Allogeneic platform on-track for planned IND submission in 2023 for first product targeting MAGE-A4 -

- Started our strategic collaboration for allogeneic T-cell therapies with Genentech - $150 million upfront payment received -

- Scaling up autologous patient supply at Navy Yard facility and construction underway of a dedicated allogeneic cell manufacturing facility in the UK -

- Appointed Cintia Piccina as Chief Commercial Officer -

- Financial guidance confirmed: funded into early 2024 -

- Conference call to be held today at 8:30 a.m. EDT (12:30 p.m. GMT) -

PHILADELPHIA, PA. and OXFORD, UK, March 14, 2022 – Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

“We are focused on four things in 2022: filing our first BLA, building our MAGE-A4 franchise, scaling up our manufacturing capabilities, and making progress with our allogeneic platform,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Last year, we delivered major milestones of our ‘2-2-5-2’ strategic plan. SPEARHEAD-1 met its primary endpoint and we identified further indications for late-stage development with our next-gen SPEAR T-cells targeting MAGE-A4. Furthermore, not only did we enter a strategic collaboration with Genentech, but we also made tremendous progress with our wholly owned allogeneic therapy targeting MAGE-A4, which is on-track for an IND in 2023.”

Progress with the Company’s “2-2-5-2” strategic plan to be delivered by 2025

“2” marketed SPEAR T-cell products targeting MAGE-A4

Roadmap to BLA submission for afami-cel¹ in 2022 (first-generation product targeting MAGE-A4)

●

Advanced/metastatic synovial sarcoma is a rare and clinically challenging disease, with no clear standard of care after progression following chemotherapy, with reported response rates with second line therapies of 18% or lower

●

SPEARHEAD-1 has met its primary endpoint²

¹ Afamitresgene autoleucel “afami-cel” (formerly ADP-A2M4)

² The primary endpoint is evaluated using a one-sided exact-based Clopper-Pearson 97.5% confidence interval (CI). Because the lower bound of the CI exceeds the response rate reported with historical second line therapy(ies) (18%), the trial has met the pre-specified threshold for demonstrating efficacy.

●

As of the data cut-off of September 1, 2021 (CTOS), the overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with myxoid/ round cell liposarcoma [MRCLS])

●

Afami-cel continues to show a favorable benefit:risk profile with more than 100 patients treated to date across multiple trials

●

Cohort 1 of the SPEARHEAD-1 trial has completed, and treatment in Cohort 2 initiated in 2021

●

Pediatric plans agreed with regulatory agencies

●

Adaptimmune is commencing preparation of the BLA and targeting a BLA submission to the US Food and Drug Administration (FDA) in Q4 2022

Further indications for late-stage clinical development for SPEAR T-cells targeting MAGE-A4

●

Initiated recruitment in the Phase 2 SURPASS-2 trial for people with esophageal and esophagogastric junction (EGJ) cancers

●

Initiating the Phase 2 SURPASS-3 trial for people with ovarian cancer in 2022

“2” additional BLAs for SPEAR T-cell products targeting MAGE-A4

Phase 1 SURPASS trial with next-generation ADP-A2M4CD8 SPEAR T-cells targeting MAGE-A4

●

Overall response rate of 36% with a complete response in ovarian cancer, and partial responses in ovarian, head and neck, EGJ, bladder, and synovial sarcoma cancers (ESMO 2021)

●

Most patients experienced antitumor activity with a disease control rate of 86% (ESMO 2021)

●

The benefit:risk profile of ADP-A2M4CD8 cell therapy remains favorable

●

The SURPASS trial continues to enroll, focusing on people with gastroesophageal, head and neck, lung, bladder, and ovarian cancers

●

Combination with a checkpoint inhibitor to be started this year

●

Data confirmed preclinical observations that the enhanced TCR interaction in ADP-A2M4CD8 results in a more potent product (SITC 2021)

Other clinical updates

●

Closed enrollment in the SPEARHEAD-2 trial investigating afami-cel in combination with a checkpoint inhibitor for people with head and neck cancer in 2021

●

Presented data from the radiation sub-study of the completed Phase 1 trial with afami-cel (SITC 2021), which closed to enrollment in 2021

●

Reported clinical benefit to people with liver cancer from the Phase 1 ADP-A2AFP trial (ILCA 2021)

o

This trial closed to screening in 2021

o

The Company continues to focus development on new cell therapies to target liver cancer

“5” autologous products in the clinic

Preclinical pipeline update

●

Filed a clinical trial application (CTA) for tumor-infiltrating lymphocytes (TILs) incorporating IL-7 (a potent stimulator of T-cell proliferation and survival) in collaboration with the Center for Cancer Immune Therapy (CCIT, a leading TIL center) in Denmark, with the intent to initiate a single-center clinical trial in 2022

●

Planning to initiate a Phase 1 trial in multiple indications with a new next-generation SPEAR T-cell targeting MAGE-A4, being developed in collaboration with Noile-Immune Biotech Inc., that incorporates IL-7 and CCL19 (to increase migration of SPEAR T-cells into tumors)

●

Adaptimmune continues to develop TCRs to additional HLAs and new targets, as well as further next-generation approaches

Financial Results for the fourth quarter and year ended December 31, 2021

●

Cash / liquidity position: As of December 31, 2021, Adaptimmune had cash and cash equivalents of $149.9 million and Total Liquidity³ of $369.6 million, compared to $56.9 million and $368.2 million, respectively, as of December 31, 2020.

●

Revenue: Revenue for the fourth quarter and year ended December 31, 2021 was $1.4 million and $6.1 million, respectively, compared to $1.5 million and $4.0 million for the same periods in 2020. Revenue for the year ended December 31, 2021 has increased primarily due to an increase in development activities under our collaboration arrangements.

●

Research and development (R&D) expenses: R&D expenses for the fourth quarter and year ended December 31, 2021 were $29.5 million and $111.1 million, respectively, compared to $25.8 million and $91.6 million for the same periods in 2020. R&D expenses increased due to an increase in the number of employees engaged in research and development, increases in subcontracted expenditures, and an increase in share-based compensation costs. These increases were partially offset by an increase in reimbursements receivable for research and development tax and expenditure credits.

●

General and administrative (G&A) expenses: G&A expenses for the fourth quarter and year ended December 31, 2021 were $14.8 million and $57.3 million, respectively, compared to $13.2 million and $45.8 million for the same periods in 2020 due to increases in employee-related costs, share-based compensation expense, and professional fees.

●

Net loss: Net loss attributable to holders of the Company’s ordinary shares for the fourth quarter and year ended December 31, 2021 was $38.8 million and $158.1 million respectively ($(0.04) and $(0.17) per ordinary share), compared to $36.6 million and $130.1 million ($(0.04) and $(0.15) per ordinary share) for the same periods in 2020.

Financial Guidance

The Company believes that its existing cash, cash equivalents and marketable securities, together with the upfront and additional payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company’s current operations into early 2024, as further detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission prior to this earnings release.

Conference Call Information

The Company will host a live teleconference and webcast to provide additional details at 8:30 a.m. EDT (12:30 p.m. GMT) today, March 14, 2022. The live webcast of the conference call will be available via the Events page of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial (833) 652-5917 (US or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (1343635).

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

³ Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 14, 2022 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Total Liquidity (a non-GAAP financial measure)

Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in millions):


	December 31,		December 31,
	2021		2020
Cash and cash equivalents	$	149,948	$	56,882
Marketable securities - available-for-sale debt securities		219,632		311,335
Total Liquidity	$	369,580	$	368,217

The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage.

Condensed Consolidated Statement of Operations

(unaudited, in thousands, except per share data)



	Three months ended				Year ended
	December 31,				December 31,
	2021		2020		2021		2020
Development revenue		1,417		1,502		6,149		1,122
Revenue	$	1,417	$	1,502	$	6,149	$	3,958
Operating expenses
Research and development		(29,505)		(25,777)		(111,090)		(91,568)
General and administrative		(14,776)		(13,238)		(57,305)		(45,795)
Total operating expenses		(44,281)		(39,015)		(168,395)		(137,363)
Operating loss		(42,864)		(37,513)		(162,246)		(133,405)
Interest income		179		538		1,095		2,313
Other income (expense), net		4,036		414		3,852		1,162
Loss before income tax expense		(38,649)		(36,561)		(157,299)		(129,930)
Income tax expense		(210)		(52)		(791)		(162)
Net loss attributable to ordinary shareholders	$	(38,859)	$	(36,613)	$	(158,090)	$	(130,092)

Net loss per ordinary share
Basic and diluted	$	(0.04)	$	(0.04)	$	(0.17)	$	(0.15)

Weighted average shares outstanding:
Basic and diluted		937,328,712		928,676,161		934,833,017		854,783,763

Condensed Consolidated Balance Sheets

(unaudited, in thousands, except share data)


	December 31,		December 31,
	2021		2020
Assets
Current assets
Cash and cash equivalents	$	149,948	$	56,882
Marketable securities - available-for-sale debt securities		219,632		311,335
Accounts receivable, net of allowance for doubtful accounts of $0 and $0		752		139
Other current assets and prepaid expenses		45,126		29,796
Total current assets		415,458		398,152

Restricted cash		1,718		4,602
Operating lease right-of-use assets, net of accumulated amortization		20,875		18,880
Property, plant and equipment, net of accumulated depreciation of $36,253 (2020: $31,097)		30,494		27,778
Intangible assets, net of accumulated amortization		1,000		1,730
Total assets	$	469,545	$	451,142

Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	8,113	$	6,389
Operating lease liabilities, current		2,320		2,773
Accrued expenses and other accrued liabilities		29,909		27,079
Deferred revenue, current		22,199		2,832
Total current liabilities		62,541		39,073

Operating lease liabilities, non-current		23,148		20,938
Deferred revenue, non-current		177,223		49,260
Other liabilities, non-current		673		644
Total liabilities		263,585		109,915

Stockholders’ equity
Common stock - Ordinary shares par value £0.001, 1,240,853,520 authorized and 937,547,934 issued and outstanding (2020: 1,038,249,630 authorized and 928,754,958 issued and outstanding)		1,337		1,325
Additional paid in capital		959,611		935,706
Accumulated other comprehensive loss		(11,142)		(10,048)
Accumulated deficit		(743,846)		(585,756)
Total stockholders' equity		205,960		341,227

Total liabilities and stockholders’ equity	$	469,545	$	451,142

Condensed Consolidated Cash Flow Statement

(unaudited, in thousands)


	Year ended		Year ended
	December 31,		December 31,
	2021		2020
Cash flows from operating activities
Net loss	$	(158,090)	$	(130,092)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		5,630		6,627
Amortization		937		967
Share-based compensation expense		20,629		10,414
Unrealized foreign exchange gains/(losses)		540		(1,333)
Amortization/(accretion) on available-for-sale debt securities		5,276		3,836
Other		1,173		(55)
Changes in operating assets and liabilities:
(Increase)/decrease in receivables and other operating assets		(19,358)		1,747
Decrease/(increase) in non-current operating assets		—		2,458
Increase in payables and other current liabilities		4,207		3,867
Increase in deferred revenue		149,785		47,973
Net cash provided by/(used in) operating activities		10,729		(53,591)

Cash flows from investing activities
Acquisition of property, plant and equipment		(8,574)		(2,341)
Acquisition of intangible assets		(207)		(565)
Maturity or redemption of marketable securities		224,343		105,022
Investment in marketable securities		(139,762)		(381,040)
Net cash provided by/(used in) investing activities		75,800		(278,924)

Cash flows from financing activities
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs		2,529		334,388
Proceeds from exercise of stock options		759		5,663
Net cash provided by financing activities		3,288		340,051

Effect of currency exchange rate changes on cash, cash equivalents and restricted cash		365		(960)
Net increase/(decrease) in cash, cash equivalents and restricted cash		90,182		6,576
Cash, cash equivalents and restricted cash at start of period		61,484		54,908
Cash, cash equivalents and restricted cash at end of period	$	151,666	$	61,484